RANK ligand


Also found in: Medical.

RANK ligand

[¦raŋk ′līg·ənd]
(biochemistry)
A local paracrine factor that originates from osteoblasts and mediates the effects of most, if not all, agents that are known to impact osteoclast development in bone. Also known as osteoprotegerin ligand.
References in periodicals archive ?
XGEVA is the first fully human monoclonal antibody that binds to and neutralizes RANK ligand (RANKL) a protein essential for the formation, function and survival of osteoclasts, cells which break down bone thereby inhibiting osteoclast-mediated bone destruction.
It is a fully human monoclonal antibody that binds to and neutralises RANK ligand (RANKL), a protein essential for the formation, function and survival of osteoclasts, which break down bone, thereby inhibiting osteoclast-mediated bone destruction.
XGEVA is a fully human monoclonal antibody that binds to and neutralizes RANK ligand (RANKL)--a protein essential for the formation, function and survival of osteoclasts, which break down bone--thereby inhibiting osteoclast-mediated bone destruction.
Key Words: Bone metastases, cancer-induced bone disease, cancer therapy induced bone loss, skeletal-related event (SRE), bisphosphonates, RANK ligand inhibitors, zoledronic acid, denosumab, hypocalcemia, osteonecrosis of the jaw, skeletal health.
Two years ago, the FDA approved denosumab, a subcutaneous injectable agent that is a RANK ligand inhibitor.
XGEVA is the first and only RANK Ligand inhibitor approved by the FDA indicated for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors.
The original 3-year results of FREEDOM were instrumental in winning marketing approval of the novel RANK ligand inhibitor for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Denosumab, a RANK ligand inhibitor, was first approved in June 2010 for treating postmenopausal women with osteoporosis at high risk of fracture and is marketed as Prolia.
By targeting RANK Ligand, Prolia offers an innovative new approach that helps reduce fracture risk.
Further studies identified the RANK ligand pathway as the key cell-signalling pathway responsible for the indirect control of breast stem cells in pregnancy.
Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, an essential regulator of osteoclasts (the cells that break down bone).